Biochemical Parameters in Patients Using Teriparatide

Teriparatide (TPT) is the active 1-34 amino add sequence with osteoanabolic use for severe osteoporosis. Our aim is to analyze the biochemical and clinical profile of patients treated with TPT based on Romanian protocol. The inclusion and exclusion criteria are based on specific country protocol for TPT 20 mu g/day, for 2 years, once in life time based on self administration. This is a transversal study including data of a tertiary centre of endocrinology on patients who signed the informed consent. This is a real life study, of observational type (the intervention meaning the TPT recommendation was done by individual decision of each clinician). Normal total and ionic calcium is associated with low 25-hydroxyvitamin D levels and a mean lumbar T-score of -3. 1 +/- 0.7SD. 50% of patients treated with TPT have digestive conditions, less than 10% are first time users, a high severity profile is based on a median of 4 years regarding prior anti-osteoporotic medication and of 3 previous fragility fractures.